Pfizer Initiates Clinical Study of Eighth Candidate Emerges Under the Collaboration with Sosei Heptares

 Pfizer Initiates Clinical Study of Eighth Candidate Emerges Under the Collaboration with Sosei Heptares

Pfizer Initiates Clinical Study of Eighth Candidate Emerges Under the Collaboration with Sosei Heptares

Shots:  

  • Sosei Heptares to receive $5M as milestones triggered by the dosing of the first subject in a clinical trial. In Jun’2019, Pfizer nominated the candidate for advancement and granted $3M as milestones  
  • The companies collaborated in 2015 to develop therapies directed at up to ten GPCR targets across multiple therapeutic areas. The collaboration has deployed Sosei Heptares’ StaR technology and SBDD capabilities to design oral small molecules modulating different GPCR targets across Pfizer’s areas of interest
  • Pfizer is responsible for developing and commercializing therapies for each target and has exclusive global rights to any resulting agents. This is the eighth GPCR-targeted drug candidate to enter clinical trials

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post